The partnership centers on ALT-B4, a recombinant human hyaluronidase enzyme that allows patients to receive medications via injection rather than lengthy IV infusions. By temporarily modifying the extracellular matrix, the technology accelerates drug absorption, offering a more convenient administration route for patients. Under the contract, Novartis gains multiple options to apply this platform to a range of its internal therapeutic products.
In section Releases
Alteogen Inks $3.2 Billion Licensing Deal with Novartis
Novartis has secured rights to deploy Alteogen’s proprietary Hybrozyme™ technology across its drug pipeline, aiming to transition intravenous treatments into subcutaneous formulations. The agreement marks a significant expansion for the South Korean firm, potentially netting them up to $3.22 billion if all development milestones and sales targets are met.
This deal represents the fourth licensing agreement for Alteogen this year, underscoring the growing industry demand for subcutaneous delivery systems. CEO Tae-Yon Chun noted that Novartis’ decision to integrate the platform across various modalities validates the commercial utility of the Hybrozyme™ tech. Should the collaboration progress through all phases, Alteogen will collect a combination of exercise fees, development bonuses, and ongoing royalties on net product sales.
Comments (0)
No comments yet. Be the first!